MCRB

Seres Therapeutics Inc

MCRB, USA

Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize gastrointestinal pathogens, enhance epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. Its other pipeline programs include SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease; and SER-287 and SER-301, which are in clinical trials for the treatment of mild-to-moderate ulcerative colitis. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

https://www.serestherapeutics.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
MCRB
stock
MCRB

Head-To-Head Contrast: Castle Biosciences (NASDAQ:CSTL) versus Seres Therapeutics (NASDAQ:MCRB) Defense World

Read more →
MCRB
stock
MCRB

Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Above 50 Day Moving Average - Here's What Happened MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$21

Analyst Picks

Strong Buy

2

Buy

0

Hold

2

Sell

1

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

High

19.70

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very High

3.40

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

High

18.77 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Medium

5.72 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

626.21 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

2.28

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 32.28% of the total shares of Seres Therapeutics Inc

1.

Flagship Ventures Management, Inc.

(13.2028%)

since

2025/06/30

2.

Vanguard Group Inc

(3.3365%)

since

2025/06/30

3.

FMR Inc

(3.0693%)

since

2025/06/30

4.

Vanguard Total Stock Mkt Idx Inv

(2.1554%)

since

2025/07/31

5.

BlackRock Inc

(1.1577%)

since

2025/06/30

6.

Geode Capital Management, LLC

(1.0463%)

since

2025/06/30

7.

Marshall Wace Asset Management Ltd

(1.0441%)

since

2025/06/30

8.

Vontobel Holding Ltd.

(0.9175%)

since

2025/06/30

9.

Vanguard Institutional Extnd Mkt Idx Tr

(0.8809%)

since

2025/07/31

10.

LUX IM Global Medtech HX

(0.5494%)

since

2025/08/31

11.

Fidelity Extended Market Index

(0.4439%)

since

2025/07/31

12.

Charles Schwab Investment Management Inc

(0.3984%)

since

2025/06/30

13.

Schwab US Small-Cap ETFâ„¢

(0.3982%)

since

2025/08/30

14.

State Street Corp

(0.3065%)

since

2025/06/30

15.

XTX Topco Ltd

(0.2561%)

since

2025/06/30

16.

Squarepoint Ops LLC

(0.2388%)

since

2025/06/30

17.

Fidelity VIP Growth Initial

(0.2317%)

since

2025/07/31

18.

Lion Point Capital, LP

(0.1946%)

since

2025/06/30

19.

Northern Trust Corp

(0.1722%)

since

2025/06/30

20.

iShares Micro-Cap ETF

(0.1707%)

since

2025/08/31

21.

Extended Equity Market Fund K

(0.1649%)

since

2025/06/30

22.

Fidelity Total Market Index

(0.1598%)

since

2025/07/31

23.

TANG CAPITAL MANAGEMENT LLC

(0.159%)

since

2025/06/30

24.

Fidelity Growth Company Fund

(0.1492%)

since

2025/07/31

25.

Bridgeway Capital Management, LLC

(0.1428%)

since

2025/06/30

26.

Bridgeway Ultra-Small Company Market

(0.1428%)

since

2025/06/30

27.

Fidelity Advisor Equity Growth I

(0.134%)

since

2025/07/31

28.

Susquehanna International Group, LLP

(0.1335%)

since

2025/06/30

29.

Fidelity Series Total Market Index

(0.1159%)

since

2025/07/31

30.

Spartan Extended Market Index Pool F

(0.0994%)

since

2025/07/31

31.

Northern Trust Extended Eq Market Idx

(0.093%)

since

2025/06/30

32.

NT Ext Equity Mkt Idx Fd - L

(0.093%)

since

2025/06/30

33.

Fidelity Growth Discovery

(0.0912%)

since

2025/07/31

34.

Morgan Stanley - Brokerage Accounts

(0.0895%)

since

2025/06/30

35.

UBS Group AG

(0.086%)

since

2025/06/30

36.

Royal Bank of Canada

(0.0794%)

since

2025/06/30

37.

NT Ext Equity Mkt Idx Fd - NL

(0.0753%)

since

2025/06/30

38.

SBI Securities Co Ltd

(0.0398%)

since

2025/06/30

39.

Vanguard Instl Ttl Stck Mkt Idx Tr

(0.035%)

since

2024/12/31

40.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0222%)

since

2024/12/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

0.94

EPS Estimate

-0.0397

EPS Difference

0.9797

Surprise Percent

2467.7582%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(8)
GARP
Not Attractive for GARP(3)
Growth
Weak Growth Prospect(2.5)
Momentum
No Momentum(3)
Net Net
Possible Net-Net(4.5)
Quality
Moderate Quality(6)
Value
Fair Value(5.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.